ArticleVaccines2025

In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity.

Danjie Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.